All Press Releases
PILA PHARMA ACCELERATES THE PUBLICATION OF THE INTERIM REPORT OF THE SECOND HALF OF 2025
Malmö, 05 February 2026 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today announced that it will publish its interim report for the second half of 2025, on 10 February 2026, bringing forward the previously scheduled publication date of 26 February 2026. The reason for rescheduling is…
THE EXERCISE PRICE FOR THE WARRANTS OF SERIES TO2 IN PILA PHARMA HAS BEEN DETERMINED TO SEK 1.50 AND THE EXERCISE PERIOD COMMENCES TODAY
Malmö, 5 February 2026 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, completed a rights issue of units during the third quarter of 2025 (the "Rights Issue"). One unit consisted of one (1) share and one (1) warrant of series TO2. Each warrant of series TO2 gives…
PILA PHARMA: INVITATION TO LIVE Q&A TODAY, JANUARY 27, REGARDING PRECLINICAL STUDIES AND UPCOMING CLINICAL STUDIES
Malmö, 27 January 2026 PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today hosts an online Q&A (questions and answers) in relation to its concluded preclinical studies and upcoming clinical activities. The Company invites for a live online Q&A, today 27 January at 14:30 CET, with Direkt…